|
Hair Restoration Discussion Forum - By and For Hair Loss Patients |
|
||||||
|
Welcome! This forum has over 180,000 posts and 12,000 before and after photos going back several years. To research a topic or physician, click on "Search" and enter the name. You are currently a guest with limited access. By joining our FREE community you can post on this forum, reply privately to other members and or create your own profile, blog and photo album. Registration is easy, private and free so Join Today! If you have any problems with the registration or login process, please contact us. If you are new please visit our FAQ. |
| Hair Loss Drugs Share your opinions and experiences regarding drugs like Propecia (finasteride), Minoxidil and others. |
![]() |
|
|
LinkBack | Thread Tools | Search this Thread | Display Modes |
|
|||
|
Here is some info. that I have obtained in some research that I did. The research does seem to vary depending on where you get it--not sure why this would be. In this particular test study that I got from Dr. Bernsteins site it shows placebo results way down but I have seen studies where its far from drastic. Who really knows? Hope this helps.
Results In this phase II, dose-ranging study, 2.5-mg dutasteride was superior to 5-mg finasteride in improving scalp hair growth in men between ages 21 and 45 years with MPHL as judged by target area hair counts, expert panel assessment, and investigator assessment at 12 and 24 weeks. In a test area at 24 weeks, results showed: Placebo '†'32.3 hairs Finasteride 5mg 75.6 hairs Dutasteride 0.1 mg 78.5 hairs Dutasteride 0.5 mg 94.6 hairs Dutasteride 2.5 mg 109.6 hairs Side Effects Both dutasteride and finasteride were well tolerated in this phase II study, and no new safety concerns have arisen in any of the phase II and phase III studies of dutasteride given at doses up to 5 mg daily (the 5-mg dose was used in a phase II study for BPH). There were no significant differences in side effects, serious adverse events, or withdrawals due to adverse events among any of the treatment groups, including placebo. In total, 11 subjects withdrew because of adverse events: 3 were in the placebo group (irritable bowel syndrome and impotency), 7 in the dutasteride 0.1 mg group (decreased libido, malaise and fatigue, mood disorders, skin disorders, injuries caused by trauma, and gastrointestinal- and neurology-related complaints) and 1 in the dutasteride 0.5 mg group (gastrointestinal discomfort and pain). Decreased libido was noted in: 2 subjects in the placebo group 2 subjects in each of the 0.05-mg and 0.1-mg dutasteride groups 1 subject in the 0.5-mg dutasteride group 9 subjects in the 2.5 mg dutasteride group 3 subjects in the finasteride group Of the 9 subjects with decreased libido in the 2.5-mg dutasteride group: 4 resolved while receiving therapy 1 resolved within 3 weeks 1 resolved within 8 weeks of stopping drug therapy 1 subject, decreased libido continued after therapy had been stopped and was presumed by the subject to be unrelated to the trial or drug therapy Concerning possible sexual adverse events, there was no evidence in the present study that either dutasteride or finasteride was associated with impotence. However, 9 men in the 2.5-mg dutasteride group complained of decreased libido, compared with 1 man in the 0.5-mg dutasteride group and 3 men in the finasteride group. As with previous studies with finasteride, this adverse event was characterized as either mild or moderate in severity and often resolved with continuation of the medication. In the 4-year follow-up of the phase III trials in BPH, dutasteride (0.5 mg) was well tolerated and the incidence of the most common sexual adverse events was low and tended to decrease over time. The only subject to develop gynecomastia was in the placebo group. Duration of Effects The serum half-life of finasteride is 6 to 8 hours. Dutasteride has a serum half-life of approximately 4 weeks, and this long half-life was evident in the persistent suppression of DHT with the 0.5-mg and 2.5-mg doses after dutasteride treatment was stopped. Because of this long half-life, men being treated with dutasteride should not donate blood until at least 6 months past their last dose to prevent administration to a pregnant female transfusion recipient. |
|
||||
|
Thanks for a great post NN.
__________________
My Hair Loss Website - Hair Transplant with Dr. Siporin |
|
||||
|
Good stuff NN
Too bad it's not prescribed for hairloss yet
__________________
JOBI 1417 FUT - Dr. True 1476 FUT - Dr. True 2124 FUT - Dr. True 604 FUE - Dr. True My views are based on my personal experiences, research and objective observations. I am not a doctor. Total - 5621 FU's uncut! |
![]() |
| Thread Tools | Search this Thread |
| Display Modes | |
|
|